Importer of Controlled Substances; Notice of Application; SA INTL GMBH C/O., Sigma Aldrich Co. LLC, 19015-19016 [2013-07152]
Download as PDF
19015
Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices
recommend that the Respondent’s DEA
Certificate of Registration, Number
BJ5128067, be revoked.5
DEPARTMENT OF JUSTICE
Dated: February 12, 2013.
Gail A. Randall,
Administrative Law Judge.
Importer of Controlled Substances;
Notice of Application; SA INTL GMBH
C/O., Sigma Aldrich Co. LLC
[FR Doc. 2013–07195 Filed 3–27–13; 8:45 am]
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on February 1, 2013, SA INTL
GMBH C/O., Sigma Aldrich Co. LLC.,
3500 Dekalb Street, St. Louis, Missouri
63118, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the following basic classes of controlled
substances:
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Stepan
Company
Drug Enforcement Administration
Drug
This is notice that on February 6,
2013, Stepan Company, Natural
Products Department, 100 W. Hunter
Avenue, Maywood, New Jersey 07607,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
Coca Leaves (9040), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to
manufacture bulk controlled substance
for distribution to its customer.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
As noted in a previous notice
published in the Federal Register on
September 23, 1975, 40 FR 43745, all
applicants for registration to import a
basic class of any controlled substance
in schedules I or II are, and will
continue to be, required to demonstrate
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, that the
requirements for such registration
pursuant to 21 U.S.C. 958(a); 21 U.S.C.
823(a); and 21 CFR 1301.34(b), (c), (d),
(e), and (f) are satisfied.
Dated: March 19, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
mstockstill on DSK4VPTVN1PROD with NOTICES
[FR Doc. 2013–07147 Filed 3–27–13; 8:45 am]
BILLING CODE 4410–09–P
5 The sole basis of my recommendation is the loss
of Respondent’s state licensure. I make no findings
or conclusions concerning the other allegations
asserted in the Order to Show Cause.
VerDate Mar<15>2010
20:20 Mar 27, 2013
Jkt 229001
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Aminorex (1585) ...........................
Gamma
Hydroxybutyric
Acid
(2010).
Methaqualone (2565) ...................
Alpha-ethyltryptamine (7249) .......
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
4-Methoxyamphetamine (7411) ...
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
N-Benzylpiperazine (7493) ...........
Heroin (9200) ...............................
Normorphine (9313) .....................
Etonitazene (9624) .......................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Nabilone (7379) ............................
Phencyclidine (7471) ....................
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium, powdered (9639) .............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances for sale to
research facilities for drug testing and
analysis.
In reference to drug codes 7360 and
7370, the company plans to import a
synthetic cannabidiol and a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR
3417(2007).
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 29, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import basic classes of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
E:\FR\FM\28MRN1.SGM
28MRN1
19016
Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
CFR § 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–07150 Filed 3–27–13; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2013–07152 Filed 3–27–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Mylan
Pharmaceuticals, Inc.
Importer of Controlled Substances;
Notice of Registration; Johnson
Matthey, Inc.
By Notice dated November 19, 2012,
and published in the Federal Register
on November 27, 2012, 77 FR 70824,
Johnson Matthey, Inc., Pharmaceutical
Materials, 2003 Nolte Drive, West
Deptford, New Jersey 08066–1742, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Coca Leaves (9040) .....................
Thebaine (9333) ...........................
Opium, raw (9600) .......................
Noroxymorphone (9668) ..............
Poppy Straw Concentrate (9670)
II
II
II
II
II
The company plans to import the
listed controlled substances as raw
materials, to be used in the manufacture
of bulk controlled substances, for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Johnson Matthey, Inc., to import the
basic classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Johnson
Matthey, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
VerDate Mar<15>2010
20:20 Mar 27, 2013
Jkt 229001
By Notice dated November 27, 2012,
and published in the Federal Register
on December 5, 2012, 77 FR 72409,
Mylan Pharmaceuticals, Inc., 781
Chestnut Ridge Road, Morgantown,
West Virginia 26505, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substances:
Drug
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Methadone (9250) ........................
Morphine (9300) ...........................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Mylan Pharmaceuticals, Inc. to import
the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Mylan Pharmaceuticals, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
PO 00000
Frm 00063
Fmt 4703
Sfmt 9990
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–07143 Filed 3–27–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Patheon Pharmaceuticals, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 22, 2013,
Patheon Pharmaceuticals, Inc., 2110 E.
Galbraith Road, Cincinnati, Ohio 45237,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Gamma Hydroxybutyric
Acid (2010), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 28, 2013.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–07138 Filed 3–27–13; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\28MRN1.SGM
28MRN1
Agencies
[Federal Register Volume 78, Number 60 (Thursday, March 28, 2013)]
[Notices]
[Pages 19015-19016]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07152]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; SA INTL
GMBH C/O., Sigma Aldrich Co. LLC
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on February 1, 2013, SA INTL GMBH C/O., Sigma Aldrich
Co. LLC., 3500 Dekalb Street, St. Louis, Missouri 63118, made
application by renewal to the Drug Enforcement Administration (DEA) for
registration as an importer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
Aminorex (1585)............................ I
Gamma Hydroxybutyric Acid (2010)........... I
Methaqualone (2565)........................ I
Alpha-ethyltryptamine (7249)............... I
Ibogaine (7260)............................ I
Lysergic acid diethylamide (7315).......... I
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
4-Methoxyamphetamine (7411)................ I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
1-[1-(2-Thienyl)cyclohexyl]piperidine I
(7470).
N-Benzylpiperazine (7493).................. I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Etonitazene (9624)......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Glutethimide (2550)........................ II
Nabilone (7379)............................ II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Ecgonine (9180)............................ II
Ethylmorphine (9190)....................... II
Hydrocodone (9193)......................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Opium, powdered (9639)..................... II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
sale to research facilities for drug testing and analysis.
In reference to drug codes 7360 and 7370, the company plans to
import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No
other activity for this drug code is authorized for this registration.
Comments and requests for hearings on applications to import
narcotic raw material are not appropriate. 72 FR 3417(2007).
In regard to the non-narcotic raw material, any bulk manufacturer
who is presently, or is applying to be, registered with DEA to
manufacture such basic classes of controlled substances listed in
schedules I or II, which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 29, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import basic classes of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of
[[Page 19016]]
Diversion Control, Drug Enforcement Administration, that the
requirements for such registration pursuant to 21 U.S.C. 958(a); 21
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 20, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-07152 Filed 3-27-13; 8:45 am]
BILLING CODE 4410-09-P